Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q4 FY25 results · Jan–Mar 2025
Lincoln Pharmaceuticals reported revenue from operations of ₹168.18 crore (up 18.0% from Q4 FY24) and net profit of ₹11.57 crore (down 37.8% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 168.18 | 142.49 | +18.0% | 146.55 | +14.8% |
| Other income | (6.88) | 7.02 | Turned loss | 8.97 | Turned loss |
| Total income | 161.30 | 149.51 | +7.9% | 155.52 | +3.7% |
| Profit before tax | 16.25 | 22.22 | −26.9% | 28.68 | −43.4% |
| Net profit for the period | 11.57 | 18.60 | −37.8% | 20.77 | −44.3% |
| EPS, basic (₹) | 5.78 | 9.28 | −37.7% | 10.37 | −44.3% |
| Net margin (%) | 6.9 | 13.1 | 14.2 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 168.18 | 142.49 | +18.0% | 146.55 | +14.8% |
| Other income | (6.88) | 7.02 | Turned loss | 8.97 | Turned loss |
| Total income | 161.30 | 149.51 | +7.9% | 155.52 | +3.7% |
| Profit before tax | 16.25 | 22.22 | −26.9% | 28.68 | −43.4% |
| Net profit for the period | 11.57 | 18.60 | −37.8% | 20.77 | −44.3% |
| EPS, basic (₹) | 5.78 | 9.28 | −37.7% | 10.37 | −44.3% |
| Net margin (%) | 6.9 | 13.1 | 14.2 |
Consolidated
- Filed with BSE
- 22 May 2025, 19:30 IST
- Board meeting
- 22 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 22 May 2025, 19:30 IST
- Board meeting
- 22 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE